Description

S4 Powder (Andarine) – Industrial Grade Bulk Supply

Product Details Table

 

S-4 (Andarine) Capsules | First-Generation SARM for Androgen Receptor Research | BioSynLab

BioSynLab presents pharmaceutical-grade S-4 (Andarine) in convenient capsule formulation for advanced androgen receptor research, partial agonist studies, and comparative SARM pharmacology. As one of the first non-steroidal SARMs developed, Andarine serves as a critical historical reference compound for investigating tissue-selective androgen signaling, partial agonist mechanisms, and off-target receptor interactions in laboratory settings.

Chemical Architecture & First-Generation SARM Design

S-4 (Andarine, GTX-007) represents the aryl propionamide class of first-generation SARMs, featuring a distinctive structural scaffold that established the foundation for subsequent SARM development:

Structural Features:

• Aryl Propionamide Core: Non-steroidal backbone with anabolic activity
• Cyanonitro Substitution: Electron-withdrawing groups optimizing receptor binding
• Trifluoromethyl Group: Metabolic stability enhancement
• Hydroxyl Moiety: Hydrogen bonding capability with AR ligand-binding domain

Mechanism of Action:

• Androgen Receptor Partial Agonist: Lower intrinsic activity than full agonists (testosterone, DHT)
• Tissue-Selective Activity: Anabolic effects in muscle and bone with reduced prostate stimulation
• Binding Affinity: Ki ~4 nM (moderate affinity vs. newer SARMs)
• Metabolism: Extensive first-pass hepatic metabolism to active metabolites

Physicochemical Properties:

• Molecular weight: 441.36 g/mol (higher than LGD-4033)
• Calculated LogP: 2.8 (moderate lipophilicity)
• pKa: Non-ionizable (neutral molecule)
• Melting point: 70-75°C (amorphous solid tendency)
• Chirality: Single enantiomer (chiral center in propionamide)

Capsule Formulation & Pharmaceutical Engineering

Our S-4 capsules utilize precision formulation technology:

Excipient Composition:

• Active Pharmaceutical Ingredient: S-4 – 25mg, 50mg, or 75mg
• Diluent: Microcrystalline cellulose (Avicel PH-102) – 100-250mg
• Glidant: Silicon dioxide (Aerosil) – 2-5mg
• Lubricant: Magnesium stearate – 2-3mg

Capsule Specifications:

Quality Attributes:

• Content uniformity: RSD <6% (USP <905>)
• Weight variation: Meets USP <905> criteria
• Disintegration: <30 minutes (USP <701>)
• Dissolution: >75% in 45 minutes

Packaging Options:

• HDPE bottles: 30, 60, 90 count with desiccant canister
• Blister packs: 10 capsules per sheet, child-resistant
• Bulk packaging: 500, 1000 count for institutional orders

Analytical Characterization & Quality Verification

Each BioSynLab S-4 batch undergoes comprehensive analytical profiling:

Chromatographic Analysis:

• HPLC-UV (220nm): ≥99.0% purity
• Chiral HPLC: Enantiomeric purity >99% ee
• Related substances: <1.0% total impurities
• Residual solvents: Meets ICH Q3C

Mass Spectrometry:

• LC-MS/MS: [M+H]⁺ at m/z 442.1, characteristic fragmentation
• High-Resolution MS: Exact mass <5 ppm deviation

Nuclear Magnetic Resonance (NMR):

• ¹H NMR (500MHz, DMSO-d₆):
  • Aromatic protons: δ 6.8-8.0 (m, 8H)
  • Propionamide CH: δ 3.45 (m, 1H)
  • Hydroxyl: δ 5.95 (br s, 1H)
  • CF₃: δ Not observed (¹⁹F NMR)
• ¹⁹F NMR: Single signal at δ -61.8 ppm
• ¹³C NMR (125MHz): 19 distinct carbon signals
• FTIR: O-H (3400 cm⁻¹), C=O (1660, 1680 cm⁻¹), C-F (1120 cm⁻¹), NO₂ (1550 cm⁻¹)

Physical Testing:

• Water content: <0.5% (Karl Fischer)
• Heavy metals: <10 ppm (ICP-MS)
• Specific rotation: [α]²⁰D = -15° to -19° (c=1, methanol)
• Residue on ignition: <0.1%

Research Applications & Scientific Significance

S-4 capsules serve critical functions in multiple research disciplines:

Androgen Receptor Pharmacology:

• Partial agonist characterization (intrinsic activity studies)
• Tissue-selective gene expression (muscle vs. prostate)
• Coactivator recruitment differences (vs. full agonists)
• Historical SARM comparison (first-gen vs. second-gen)

Off-Target Research:

• Ocular receptor binding (vision side effect mechanism)
• Retinal pigment epithelium studies
• Night vision impairment modeling
• Selectivity improvement research (driving development of newer SARMs)

Musculoskeletal Research:

• Muscle atrophy models (cancer, disuse, aging)
• Bone density studies (osteoporosis models)
• Fracture healing research
• Comparison with LGD-4033/MK-2866

Metabolic Studies:

• Body composition analysis
• Lipid profile effects (HDL/LDL changes)
• Insulin sensitivity research
• Energy expenditure quantification

Historical & Comparative Research:

• First-generation SARM benchmark
• Structure-activity evolution (S-4 → Ostarine → Ligandrol)
• Clinical discontinuation rationale studies (vision effects)
• Regulatory development impact

Global Distribution & Discrete Procurement

BioSynLab provides secure, compliant distribution:

Packaging Specifications:

• Primary: Hard gelatin capsules in HDPE bottles or blister packs
• Secondary: Tamper-evident seals, desiccant chambers
• Tertiary: Discrete unmarked shipping containers

Shipping Options:

• Standard: Ambient temperature, 5-7 days
• Express: Tracked courier, 2-3 days
• Discrete: No product identifiers, generic return addresses

Service Coverage:

United Kingdom: London, Manchester, Birmingham, Leeds, Glasgow, Liverpool, Sheffield, Bristol, Edinburgh, Cardiff, Belfast, Nottingham, Leicester.

European Union: Berlin, Hamburg, Munich, Cologne, Frankfurt, Amsterdam, Rotterdam, Paris, Lyon, Barcelona, Madrid, Rome, Milan, Vienna, Brussels, Prague, Warsaw.

North America: New York, Los Angeles, Chicago, Houston, Philadelphia, San Antonio, San Diego, Dallas, San Jose, Austin, Toronto, Vancouver.